Is producing a non-profit Covid-19 vaccine a smart decision for AstraZeneca and the industry

Is producing a non-profit Covid-19 vaccine a smart decision for AstraZeneca and the industry

AZN's market-cap breached the £100bn break-out line thanks to the Covid-crisis, the British pharma giant promised that during the pandemic it won’t make profit on the vaccine, but maybe it should.         AZN.L relative 12m share price performance (lighter line) vs....

Continue reading →